

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	9	JUL 27	CA/CAplus enhanced with new citing references
NEWS	10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	11	JUL 21	USGENE adds bibliographic and sequence information
NEWS	12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS	13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS	14	AUG 08	Improve STN by completing a survey and be entered to win a gift card
NEWS	15	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	16	AUG 17	CAS REGISTRY, the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
NEWS	17	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* *

* Please take a couple of minutes to complete our short survey. Your *
 * name will be entered to win one of five \$20 Amazon.com gift cards. *
 *
 * See NEWS 14 for details or go directly to the survey at: *
 * <http://www.zoomerang.com/Survey/?p=WEB229H4S8Q5UL> *
 *

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:54:59 ON 20 AUG 2009

```
=> file reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          0.22        0.22
```

FILE 'REGISTRY' ENTERED AT 13:55:11 ON 20 AUG 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 19 AUG 2009 HIGHEST RN 1174705-31-7
 DICTIONARY FILE UPDATES: 19 AUG 2009 HIGHEST RN 1174705-31-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Program Files\STNEXP\Queries\10586421c.str



```

chain nodes :
6 7 19 20
ring nodes :
1 2 3 4 5 9 10 11 12 13 14 15 16 17 21 22 23 24 25 26 27 28
29 30 31 32 33 34 35 36 37 38 39 40 41 42
chain bonds :
2-6 3-9 4-20 5-7 12-19
ring bonds :
1-2 1-5 2-3 3-4 4-5 9-10 9-11 10-13 10-14 11-12 12-13 13-17 14-15
15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 28-33
29-30 29-36 30-31 31-32 33-34 34-35 35-36 37-38 37-42 38-39 39-40 40-41
41-42
exact/norm bonds :
1-2 1-5 2-6 4-20 5-7 11-12 12-13 12-19
exact bonds :
2-3 3-4 3-9 4-5 9-10 9-11
normalized bonds :
10-13 10-14 13-17 14-15 15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26
27-28 27-32 28-29 28-33 29-30 29-36 30-31 31-32 33-34 34-35 35-36 37-38
37-42 38-39 39-40 40-41 41-42
isolated ring systems :
containing 1 : 9 :

```

G1:H,Ak

G2:[*1],[*2],[*3]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom
40:Atom 41:Atom 42:Atom

L1 STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 13:55:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1191 TO ITERATE

100.0% PROCESSED 1191 ITERATIONS 285 ANSWERS
SEARCH TIME: 00.00.01

L2 285 SEA SSS FUL L1

=> file capl		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 13:55:52 ON 20 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Aug 2009 VOL 151 ISS 8
FILE LAST UPDATED: 19 Aug 2009 (20090819/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/Caplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s 12

L3 23 L2

=> d 13 1-23 ibib hitstr

L3 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1456522 CAPLUS

DOCUMENT NUMBER: 150:229049

TITLE: Recent progress in indolylmaleimide derivatives as protein kinase C inhibitors

AUTHOR(S): Zhao, Sheng-Yin; Shao, Zhi-Yu; Qin, Wei-Min; Zhang, Deng-Qing

CORPORATE SOURCE: College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, Peop. Rep. China

SOURCE: Youji Huaxue (2008), 28(10), 1676-1684

CODEN: YCHHDX; ISSN: 0253-2786

PUBLISHER: Youji Huaxue Bianjibu

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Chinese

OTHER SOURCE(S): CASREACT 150:229049


IT 125313-42-0P 221233-51-8P 860646-70-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(recent progress in indolylmaleimide derivs. as protein kinase C inhibitors)


RN 125313-42-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)




RN 221233-51-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 860646-70-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:398759 CAPLUS

DOCUMENT NUMBER: 148:528866

TITLE: Aryl-indolyl maleimides as inhibitors of

CaMKII δ . Part 1: SAR of the aryl region

AUTHOR(S): Levy, Daniel E.; Wang, Dan-Xiong; Lu, Qing; Chen, Zheng; Perumattam, John; Xu, Yong-jin; Liclican, Albert; Higaki, Jeffrey; Dong, Hanmin; Laney, Maureen; Mavunkel, Babu; Dugar, Sundeep

CORPORATE SOURCE: Scios, Inc., Fremont, CA, 94555, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(7), 2390-2394

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:528866

IT 1024583-89-8P 1024583-91-2P 1024583-96-7P


1024583-97-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(aryl-indolyl maleimides as inhibitors of CaMKII δ)

RN 1024583-89-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 1024583-91-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(4-quinolinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 1024583-96-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 1024583-97-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(4-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 1024584-17-5P 1024584-19-7P 1024584-22-2P
 1024584-23-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (aryl-indolyl maleimides as inhibitors of CaMKIIS)
 RN 1024584-17-5 CAPLUS
 CN Carbamic acid, N-[3-[3-[2,5-dihydro-4-(1-naphthalenyl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1024584-19-7 CAPLUS
 CN Carbamic acid, N-[3-[3-[2,5-dihydro-2,5-dioxo-4-(4-quinolinyl)-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1024584-22-2 CAPLUS

CN Carbamic acid, N-[3-[3-[2,5-dihydro-2,5-dioxo-4-(3-pyridinyl)-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1024584-23-3 CAPLUS


CN Carbamic acid, N-[3-[3-[2,5-dihydro-2,5-dioxo-4-(4-pyridinyl)-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2008:304093 CAPLUS
 DOCUMENT NUMBER: 148:517486
 TITLE: Efficient palladium-catalyzed synthesis of
 3-aryl-4-indolylmaleimides
 AUTHOR(S): Pews-Davtyan, Anahit; Tillack, Annegret; Ortinau,
 Stefanie; Rolfs, Arndt; Beller, Matthias
 CORPORATE SOURCE: Leibniz-Institut fuer Katalyse e.V. an der
 Universitaet Rostock, Rostock, D-18059, Germany
 SOURCE: Organic & Biomolecular Chemistry (2008), 6(6), 992-997
 CODEN: OBCRAK; ISSN: 1477-0520
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 148:517486
 IT 1021953-08-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of arylindolylmaleimides via palladium-phosphine-catalyzed
 cross-coupling of arylboronic acids with bromo(methylindolyl)maleimide)
 RN 1021953-08-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 1-methyl-3-(2-methyl-1H-indol-3-yl)-4-(4-pyridinyl)-
 (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:557922 CAPLUS
 DOCUMENT NUMBER: 146:501190
 TITLE: Metal complex glycogen synthase kinase 3 inhibitors
 INVENTOR(S): Meggers, Eric; Bregman, Howard; Williams, Douglas S.
 PATENT ASSIGNEE(S): The University of Pennsylvania, USA
 SOURCE: U.S. Pat. Appl. Publ., 30 pp., Cont. of U.S. Appl.
 20050171076.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060019942	A1	20060126	US 2005-228381	20050919
US 20050171076	A1	20050804	US 2005-45331	20050131
US 7488817	B2	20090210		
PRIORITY APPLN. INFO.:			US 2004-540591P	P 20040202
			US 2004-610607P	P 20040917

US 2005-45331

A1 20050131


OTHER SOURCE(S):

CASREACT 146:501190; MARPAT 146:501190

IT 799822-54-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation of nitrogen heterocyclic ruthenium metal complexes as glycogen
synthase kinase 3 inhibitors)

RN 799822-54-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(3-pyridinyl)-4-[1-[[2-
(trimethylsilyl)ethoxy]methyl]-1H-indol-3-yl]- (CA INDEX NAME)Me₃Si-CH₂-CH₂-O-CH₂

L3 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:54639 CAPLUS

DOCUMENT NUMBER: 146:163003

TITLE: Indolylmaleimide derivatives as protein kinase
inhibitors and their preparation, pharmaceutical
compositions and use in the prevention and treatment
of T lymphocyte mediated diseasesINVENTOR(S): Wagner, Juergen; Van Eis, Maurice; Von Matt, Peter;
Evenou, Jean-Pierre; Schuler, Walter

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 68pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007006533	A2	20070118	WO 2006-EP6732	20060710
WO 2007006533	A3	20070524		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006268908	A1	20070118	AU 2006-268908	20060710
CA 2611607	A1	20070118	CA 2006-2611607	20060710
EP 1904482	A2	20080402	EP 2006-754708	20060710

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2009501172 T 20090115 JP 2008-520772 20060710
 IN 2007DN09350 A 20080627 IN 2007-DN9350 20071204
 MX 2008000463 A 20080311 MX 2008-463 20080109
 KR 2008023732 A 20080314 KR 2008-700790 20080110
 CN 101223162 A 20080716 CN 2006-80025403 20080111
 US 20080318975 A1 20081225 US 2008-995450 20080805
 PRIORITY APPLN. INFO.: GB 2005-14204 A 20050711
 GB 2005-14205 A 20050711
 WO 2006-EP6732 W 20060710

OTHER SOURCE(S): MARPAT 146:163003


IT	860468-19-5P	919992-55-5P	919992-56-6P
	919992-57-7P	919992-58-8P	919992-59-9P
	919992-60-2P	919992-61-3P	919992-62-4P
	919992-63-5P	919992-64-6P	919992-65-7P
	919992-66-8P	919992-67-9P	919992-68-0P
	919992-69-1P	919992-70-4P	919992-71-5P
	919992-72-6P	919992-73-7P	919992-75-9P
	919992-76-0P	919992-77-1P	919992-78-2P
	919992-79-3P	919992-80-6P	919992-83-9P
	919992-84-0P	919992-85-1P	919992-86-2P
	919992-87-3P	919992-88-4P	919992-89-5P
	919992-90-8P	919992-91-9P	919992-92-0P
	919992-93-1P	919992-94-2P	919992-95-3P
	919992-96-4P	919992-97-5P	919992-98-6P
	919992-99-7P	919993-00-3P	919993-01-4P
	919993-03-6P	919993-04-7P	919993-05-8P
	919993-06-9P	919993-07-0P	919993-08-1P
	919993-09-2P	919993-10-5P	919993-11-6P
	919993-12-7P	919993-13-8P	919993-14-9P
	919993-15-0P	919993-16-1P	919993-17-2P
	919993-18-3P	919993-19-4P	919993-20-7P
	919993-21-8P	919993-23-0P	919993-24-1P
	919993-25-2P	919993-26-3P	919993-27-4P
	919993-28-5P	919993-29-6P	919993-30-9P
	919993-31-0P	919993-32-1P	919993-33-2P
	919993-34-3P	919993-35-4P	919993-36-5P
	919993-37-6P	919993-38-7P	919993-39-8P
	919993-40-1P	919993-41-2P	919993-42-3P
	919993-43-4P	919993-44-5P	919993-45-6P
	919993-46-7P	919993-47-8P	919993-48-9P
	919993-49-0P	919993-50-3P	919993-51-4P
	919993-52-5P	919993-53-6P	919993-54-7P
	919993-55-8P	919993-56-9P	919993-57-0P
	919993-58-1P	919993-59-2P	919993-60-5P
	919993-61-6P	919993-62-7P	919993-63-8P
	919993-64-9P	919993-65-0P	919993-66-1P
	919993-67-2P	919993-68-3P	919993-69-4P
	919993-70-7P	919993-71-8P	919993-72-9P
	919993-73-0P	919993-74-1P	919993-75-2P
	919993-76-3P	919993-77-4P	919993-78-5P
	919993-79-6P	919993-80-9P	919994-32-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of indolylmaleimide derivs. as protein kinase
 inhibitors and their use in the prevention and treatment of T
 lymphocyte mediated diseases)

RN 860468-19-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-
 naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-55-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)-, 2,2,2-trifluoroacetate (1:1)
 (CA INDEX NAME)


CM 1

CRN 919992-54-4
 CMF C26 H21 Cl F N3 O2




CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 919992-56-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-(2-fluoroethyl)methylamino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-57-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-58-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-59-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-60-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-(4-methylphenyl)-1H-indol-3-yl]amino]methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-61-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[[(cyclopropylmethyl)methylamino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-62-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[1-methyl-1H-indol-3-yl]amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-63-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)methylamino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-64-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-65-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)amino]methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-66-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-methoxyethyl]amino]methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-67-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-methoxyethyl]amino]methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-68-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-methoxyethyl]amino]methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-69-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methyl-2-propen-1-ylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-70-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-propen-1-ylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-71-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(cyclopropylmethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-72-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(cyclopropylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-73-7 CAPLUS
 CN Acetamide, 2-[[3-[4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-7-yl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 919992-75-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(4-methyl-1-piperazinyl)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-76-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(4-methyl-1-piperazinyl)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-77-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(3-methoxypropoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-78-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6,7-dimethoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-79-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methoxy-6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-80-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-methoxy-7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-83-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-84-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(dimethylamino)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919992-85-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-86-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[[2-(2-methoxyethyl)amino]methyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-87-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[[2-(dimethylamino)ethyl]amino]methyl]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919992-88-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2,2,2-trifluoroethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919992-89-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(3-methoxy-3-methylbutoxy)-1H-indol-3-yl]- (CA INDEX NAME)

NAME)




RN 919992-90-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-ethoxy-1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-91-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-92-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-

naphthalenyl]-4-[6-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-93-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-94-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-methoxyethyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-95-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-96-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919992-97-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-1-(2-methoxyethyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-98-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-hydroxy-2-methylpropoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-99-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxy-2-methylpropyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-00-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[1-(2-aminoethyl)-1H-indol-3-yl]-4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 919993-01-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[7-(2-aminoethoxy)-1H-indol-3-yl]-4-[2-chloro-7-
 [(dimethylamino)methyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 919993-03-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-
 naphthalenyl]-4-[7-(2-methoxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]-
 (CA INDEX NAME)




RN 919993-04-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-
 naphthalenyl]-4-[7-(2-fluoroethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-05-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2,2,2-trifluoroethoxy)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-06-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(trifluoromethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-07-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(difluoromethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-08-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-09-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-10-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[6-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-11-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-12-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-13-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(2-aminoethoxy)ethyl]-1H-indol-3-yl]-4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 919993-14-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-hydroxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-15-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(6-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-16-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(3-aminopropoxy)-1H-indol-3-yl]-4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-1H-indol-3-yl- (CA INDEX NAME)




RN 919993-17-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-hydroxy-2-methylpropoxy)ethoxy]-1H-indol-3-yl]-1H-indol-3-yl- (CA INDEX NAME)




RN 919993-18-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-19-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-20-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-1-[2-(2-methoxyethoxy)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-21-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(2-hydroxyethoxy)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-23-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[[2-(2-methoxyethoxy)ethoxy]methyl]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-24-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[(2-methoxyethoxy)methyl]-1H-indol-3-yl]- (CA INDEX NAME)

NAME)




RN 919993-25-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-hydroxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]-
(CA INDEX NAME)




RN 919993-26-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(2-methoxyethoxy)ethyl]-7-methyl-1H-indol-3-yl]-
(CA INDEX NAME)




RN 919993-27-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(2-methoxyethoxy)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-28-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-methoxyethyl)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-29-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-6-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-30-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxyethoxy)-6-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-31-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-5-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-32-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxyethoxy)-5-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-33-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-chloro-1H-indol-3-yl)- (CA INDEX NAME)



RN 919993-34-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-chloro-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-35-4 CAPLUS
 CN 1H-Indole-7-carboxylic acid, 3-[4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-, methyl ester (CA INDEX NAME)




RN 919993-36-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-hydroxyethoxy)-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-37-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(3-hydroxypropoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-38-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-hydroxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-39-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-hydroxy-2-methylpropoxy)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-40-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(pentyloxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-41-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-chloro-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-42-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-methoxyethoxy)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-43-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-44-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5,7-dimethoxy-1H-indol-3-yl)- (CA INDEX NAME)



RN 919993-45-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5,6-dimethoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-46-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(4-methyl-1-piperazinyl)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 919993-47-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-hydroxyethoxy)ethoxy]-1-methyl-1H-indol-3-yl]-
 (CA INDEX NAME)




RN 919993-48-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(methylanino)ethoxy]-1H-indol-3-yl]- (CA INDEX

NAME)




RN 919993-49-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(1H-imidazol-2-yl)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-50-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(1H-imidazol-2-yl)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-51-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-methoxy-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-52-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-hydroxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-53-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-hydroxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-54-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-methoxyethoxy)-5,7-dimethyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-55-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-5,7-dimethyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-56-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-57-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-6-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-58-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-fluoro-7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-59-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-fluoro-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-60-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-fluoro-7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-61-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxy-2-methylpropoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-62-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxy-2-methylpropoxy)ethoxy]-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-63-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-hydroxy-2-methylpropoxy)ethoxy]-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-64-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-[2-(2-methoxyethoxy)ethoxy]-1-[2-(2-

methoxyethoxy)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-65-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-chloro-7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)



RN 919993-66-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-(2-methoxyethoxy)-1-(2-methoxyethyl)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-67-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]-

(CA INDEX NAME)




RN 919993-68-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-69-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-methoxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-70-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-

naphthalenyl]-4-[1-(2-hydroxyethyl)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-71-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(3-hydroxypropyl)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-72-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(3-hydroxypropyl)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-73-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-

naphthalenyl]-4-[1-(2-hydroxyethyl)-7-methoxy-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-74-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-ethyl-7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-75-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-ethyl-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-76-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-ethyl-7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-77-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-5-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-78-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-6-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-79-6 CAPLUS

CN Acetamide, N-[[7-chloro-8-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-naphthalenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 919993-80-9 CAPLUS

CN Acetamide, N-[[7-chloro-8-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-naphthalenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 919994-32-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[[2-(dimethylamino)ethyl]methylamino]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)



IT 919994-33-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of indolylmaleimide derivs. as protein kinase

inhibitors and their use in the prevention and treatment of T
lymphocyte mediated diseases)

RN 919994-33-5 CAPLUS

CN Carbamic acid, N-[[7-chloro-8-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-
dioxo-1H-pyrrol-3-yl]-2-naphthalenyl]methyl]-N-(2-fluoroethyl)-,
1,1-dimethylethyl ester (CA INDEX NAME)



L3 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:984206 CAPLUS

DOCUMENT NUMBER: 145:505290

TITLE: A practical method for the synthesis of indolylaryl-
and bisindolylmaleimides

AUTHOR(S): Roy, Sudipta; Roy, Sujata; Gribble, Gordon W.

CORPORATE SOURCE: Department of Chemistry, Dartmouth College, Hanover,
NH, 03755, USA

SOURCE: Organic Letters (2006), 8(21), 4975-4977

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:505290


IT 125313-42-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of indolyl(aryl)maleimides via acylation of N-methylindole with
oxalyl chloride followed by amidation and cyclocondensation with
arylacetates)

RN 125313-42-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA
INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:94622 CAPLUS

DOCUMENT NUMBER: 144:350471

TITLE: Design, Synthesis, and Biological Evaluation of 3,4-Diarylmaleimides as Angiogenesis Inhibitors
AUTHOR(S): Peifer, Christian; Stoiber, Thomas; Unger, Eberhard; Totzke, Frank; Schaechtele, Christoph; Marme, Dieter; Brenk, Ruth; Klebe, Gerhard; Schollmeyer, Dieter; Dannhardt, Gerd

CORPORATE SOURCE: Department of Pharmacy, Johannes Gutenberg-University, Mainz, D-55099, Germany

SOURCE: Journal of Medicinal Chemistry (2006), 49(4), 1271-1281

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:350471


IT 221233-51-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of diarylmaleimides by cyclocondensation of arylglyoxylates with arylacetamides as angiogenesis inhibitors)

RN 221233-51-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:673288 CAPLUS

DOCUMENT NUMBER: 143:153287

TITLE: Preparation of indolylmaleimide derivatives as PKC inhibitors

INVENTOR(S): Van Eis, Maurice; Von Matt, Peter; Wagner, Juergen; Evenou, Jean-Pierre; Schuler, Walter

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068455	A1	20050728	WO 2005-EP502	20050119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005205183	A1	20050728	AU 2005-205183	20050119
CA 2552740	A1	20050728	CA 2005-2552740	20050119
EP 1745037	A1	20070124	EP 2005-701052	20050119
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1910173	A	20070207	CN 2005-80002684	20050119
BR 2005006939	A	20070612	BR 2005-6939	20050119
JP 2007518731	T	20070712	JP 2006-548287	20050119
AT 391127	T	20080415	AT 2005-701051	20050119
ES 2303218	T3	20080801	ES 2005-701051	20050119
MX 2006008158	A	20070130	MX 2006-8158	20060718
KR 2007021123	A	20070222	KR 2006-714416	20060718
IN 2006CN02629	A	20070608	IN 2006-CN2629	20060719
US 20080242675	A1	20081002	US 2006-586421	20061018
PRIORITY APPLN. INFO.:			GB 2004-1089	A 20040119
			GB 2004-1090	A 20040119
			WO 2005-EP502	W 20050119
OTHER SOURCE(S):	CASREACT 143:153287; MARPAT 143:153287			
IT 860468-10-6P	860468-11-7P	860468-12-8P		
860468-13-9P	860468-14-0P	860468-15-1P		
860468-16-2P	860468-17-3P	860468-18-4P		
860468-19-5P	860468-20-8P	860468-21-9P		
860468-22-0P	860468-23-1P	860468-24-2P		
860468-25-3P	860468-26-4P	860468-27-5P		
860468-28-6P	860468-29-7P	860468-30-0P		
860468-31-1P	860468-32-2P	860468-33-3P		
860468-34-4P	860468-35-5P	860468-36-6P		
860468-37-7P	860468-38-8P	860468-39-9P		
860468-40-2P	860468-41-3P	860468-42-4P		
860468-43-5P	860468-44-6P	860468-45-7P		
860468-46-8P	860468-47-9P	860468-48-0P		
860468-49-1P	860468-50-4P	860468-51-5P		
860468-52-6P	860468-53-7P	860468-54-8P		
860468-55-9P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of indolylmaleimide derivs. as PKC inhibitors)				
RN 860468-10-6 CAPLUS				
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)				



RN 860468-11-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)-, acetate (1:2) (CA INDEX NAME)


CM 1

CRN 860468-10-6
 CMF C26 H22 Cl N3 O2




CM 2


CRN 64-19-7
 CMF C2 H4 O2




RN 860468-12-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-chloro-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-13-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 860468-14-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-15-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-16-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-17-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-18-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-19-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 860468-20-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-21-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-22-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(ethylmethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-23-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(diethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-24-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(ethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-25-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(1-methylethyl)amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 860468-26-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(4-methyl-1-piperazinyl)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-27-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-(1-pyrrolidinylmethyl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-28-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(1,7-dimethyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-29-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-30-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-31-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-32-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-33-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-34-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(7-amino-1-naphthalenyl)-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 860468-35-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(7-amino-1-naphthalenyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-36-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[7-[(dimethylamino)methyl]-2-fluoro-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-37-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-[(dimethylamino)methyl]-2-fluoro-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-38-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methyl-1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-3-pyridinyl]- (CA INDEX NAME)




RN 860468-39-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methyl-1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-2-nitro-3-pyridinyl]- (CA INDEX NAME)




RN 860468-40-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-3-pyridinyl]- (CA INDEX NAME)




RN 860468-41-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-3-pyridinyl]- (CA INDEX NAME)




RN 860468-42-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methyl-1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-2-(trifluoromethyl)-3-pyridinyl]- (CA INDEX NAME)




RN 860468-43-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-2-(trifluoromethyl)-3-pyridinyl]- (CA INDEX NAME)




RN 860468-44-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-2-(trifluoromethyl)-3-pyridinyl]- (CA INDEX NAME)




RN 860468-45-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[5-(4-methyl-1-piperazinyl)-2-nitro-3-pyridinyl]- (CA INDEX NAME)




RN 860468-46-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-5-(4-methyl-1-piperazinyl)-3-pyridinyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-47-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methyl-1H-indol-3-yl)-4-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]- (CA INDEX NAME)




RN 860468-48-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methyl-1H-indol-3-yl)-4-[5-methyl-2-(4-methyl-1-piperazinyl)-4-pyridinyl]- (CA INDEX NAME)




RN 860468-49-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[5-methyl-2-(4-methyl-1-piperazinyl)-4-pyridinyl]- (CA INDEX NAME)




RN 860468-50-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methyl-1H-indol-3-yl)-4-[2-(4-methyl-1-piperazinyl)-5-nitro-4-pyridinyl]- (CA INDEX NAME)




RN 860468-51-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[2-(4-methyl-1-piperazinyl)-5-nitro-4-pyridinyl]- (CA INDEX NAME)




RN 860468-52-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[5-chloro-2-(4-methyl-1-piperazinyl)-4-pyridinyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-53-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[5-chloro-2-(4-methyl-1-piperazinyl)-4-pyridinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-54-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(7-methyl-1H-indol-3-yl)-4-[2-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)-4-pyridinyl]- (CA INDEX NAME)



RN 860468-55-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[2-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)-4-pyridinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:673287 CAPLUS

DOCUMENT NUMBER: 143:172756

TITLE: Preparation of indolylmaleimide derivatives as PKC inhibitors

INVENTOR(S): Van Eis, Maurice; Von Matt, Peter; Wagner, Juergen; Evenou, Jean-Pierre

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068454	A1	20050728	WO 2005-EP501	20050119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005205182	A1	20050728	AU 2005-205182	20050119
AU 2005205182	B2	20090716		
CA 2552738	A1	20050728	CA 2005-2552738	20050119
EP 1709030	A1	20061011	EP 2005-701051	20050119
EP 1709030	B1	20080402		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN 1910174	A	20070207	CN 2005-80002734	20050119
JP 2007518730	T	20070712	JP 2006-548286	20050119
BR 2005006958	A	20070724	BR 2005-6958	20050119
AT 391127	T	20080415	AT 2005-701051	20050119
ES 2303218	T3	20080801	ES 2005-701051	20050119
MX 2006008159	A	20060920	MX 2006-8159	20060718
KR 2007020401	A	20070221	KR 2006-714418	20060718
IN 2006CN02632	A	20070608	IN 2006-CN2632	20060719
US 20080234494	A1	20080925	US 2006-586420	20060719

PRIORITY APPLN. INFO.:

	GB 2004-1089	A	20040119
	GB 2004-1090	A	20040119
	WO 2005-EP501	W	20050119

OTHER SOURCE(S): CASREACT 143:172756; MARPAT 143:172756


IT 860646-70-4P 860646-71-5P 860646-72-6P
860646-73-7P 860646-74-8P 860646-75-9P
860646-76-0P 860646-77-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of indolylmaleimide derivs. as PKC inhibitors)


RN 860646-70-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-
naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-71-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[6-(aminomethyl)-1-naphthalenyl]-4-(1-methyl-1H-
indol-3-yl)- (CA INDEX NAME)




RN 860646-72-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[6-(aminomethyl)-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 860646-73-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-74-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-75-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(methylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-76-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(methylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-77-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[6-(aminomethyl)-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:517768 CAPLUS
 DOCUMENT NUMBER: 143:172975
 TITLE: Pyrido[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-diones: Synthesis, cyclometalation, and protein kinase inhibition
 AUTHOR(S): Bregman, Howard; Williams, Douglas S.; Meggers, Eric
 CORPORATE SOURCE: Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA
 SOURCE: Synthesis (2005), (9), 1521-1527
 CODEN: SYNTBF; ISSN: 0039-7881
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:172975
 IT 799822-54-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis, cyclometalation, and protein kinase inhibition via pyrido pyrrolo carbazoledione ruthenium complexes)
 RN 799822-54-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(3-pyridinyl)-4-[1-[[2-(trimethylsilyl)ethoxy)methyl]-1H-indol-3-yl]- (CA INDEX NAME)




OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
 REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:807680 CAPLUS
 DOCUMENT NUMBER: 142:16220

TITLE: An Organometallic Inhibitor for Glycogen Synthase Kinase 3
 AUTHOR(S): Bregman, Howard; Williams, Douglas S.; Atilla, G. Ekin; Carroll, Patrick J.; Meggers, Eric
 CORPORATE SOURCE: Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA
 SOURCE: Journal of the American Chemical Society (2004), 126(42), 13594-13595
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:16220
 IT 799822-54-1P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (organometallic inhibitor for glycogen synthase kinase 3)
 RN 799822-54-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(3-pyridinyl)-4-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-indol-3-yl]- (CA INDEX NAME)

Me₃Si-CH₂-CH₂-O-CH₂



OS.CITING REF COUNT: 39 THERE ARE 39 CAPLUS RECORDS THAT CITE THIS RECORD (39 CITINGS)
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:991343 CAPLUS

DOCUMENT NUMBER: 140:42028

TITLE: Preparation of substituted 1H-pyrrole-2,5-diones as kinase inhibitors

INVENTOR(S): Zhang, Han-cheng; Maryanoff, Bruce E.; Mccomsey, David F.; White, Kimberly; Ye, Hong; Hecker, Leonard; Conway, Bruce R.; Demarest, Keith

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103663	A2	20031218	WO 2003-US17518	20030604
WO 2003103663	A3	20040708		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2488798	A1	20031218	CA 2003-2488798	20030604
AU 2003240517	A1	20031222	AU 2003-240517	20030604
US 20040054180	A1	20040318	US 2003-454561	20030604
US 7232906	B2	20070619		
EP 1513520	A2	20050316	EP 2003-731528	20030604
EP 1513520	B1	20080924		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005531607	T	20051020	JP 2004-510782	20030604
AT 409035	T	20081015	AT 2003-731528	20030604
ES 2312785	T3	20090301	ES 2003-731528	20030604
US 20070213386	A1	20070913	US 2007-800878	20070508
US 20070213387	A1	20070913	US 2007-800912	20070508


PRIORITY APPLN. INFO.:
 US 2002-386002P P 20020605
 US 2003-454561 A3 20030604
 WO 2003-US17518 W 20030604

OTHER SOURCE(S): MARPAT 140:42028


IT 634605-00-8P 634605-01-9P 634605-02-0P
 634605-03-1P 634605-04-2P 634605-34-8P
 634605-36-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of substituted 1H-pyrrole-2,5-diones as kinase inhibitors)

RN 634605-00-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-ethenyl-1H-indol-3-yl)-4-(2-hydroxy-1-
 naphthalenyl)- (CA INDEX NAME)




RN 634605-01-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-[3-(dimethylamino)-2-hydroxypropoxy]-1-
 naphthalenyl]-4-(1-ethenyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 634605-02-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2-hydroxy-1-naphthalenyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 634605-03-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(2-butyn-1-ylmethylamino)ethyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)




RN 634605-04-2 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(3-butyn-1-ylmethylamino)ethyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 634605-34-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 634605-36-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(diethylamino)ethyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:796695 CAPLUS
 DOCUMENT NUMBER: 139:307678
 TITLE: Preparation of indolylmaleimides for treating diseases or disorders mediated by T lymphocytes and/or PKC

INVENTOR(S): Evenou, Jean-Pierre; Von Matt, Peter; Wagner, Juergen;
 Zenke, Gerhard
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082859	A1	20031009	WO 2003-EP3470	20030402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2477774	A1	20031009	CA 2003-2477774	20030402
AU 2003224031	A1	20031013	AU 2003-224031	20030402
AU 2003224031	B2	20070628		
EP 1490355	A1	20041229	EP 2003-720413	20030402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008979	A	20050104	BR 2003-8979	20030402
CN 1639153	A	20050713	CN 2003-805343	20030402
CN 100351251	C	20071128		
JP 2005527563	T	20050915	JP 2003-580325	20030402
JP 4247125	B2	20090402		
NZ 535613	A	20070727	NZ 2003-535613	20030402
RU 2340610	C2	20081210	RU 2004-132203	20030402
IN 2004CN02172	A	20060303	IN 2004-CN2172	20040929
MX 2004009632	A	20050111	MX 2004-9632	20041001
US 20050119274	A1	20050602	US 2004-510027	20041001
KR 886521	B1	20090302	KR 2004-715591	20041001
NO 2004004613	A	20041026	NO 2004-4613	20041026
ZA 2004006545	A	20060531	ZA 2004-6545	20060327
US 20070032507	A1	20070208	US 2006-546690	20061012
US 7358253	B2	20080415		
US 20070037826	A1	20070215	US 2006-546693	20061012
US 7235555	B2	20070626		
KR 2007043900	A	20070425	KR 2007-707917	20070406
US 20080108628	A1	20080508	US 2007-977565	20071025
US 20080146578	A1	20080619	US 2008-34675	20080221
US 7534808	B2	20090519		

PRIORITY APPLN. INFO.:

GB 2002-7729	A	20020403
GB 2003-3323	A	20030213
WO 2003-EP3470	W	20030402
KR 2004-715591	A3	20041001
US 2004-510027	A1	20041001
US 2006-546690	A1	20061012

OTHER SOURCE(S): MARPAT 139:307678

IT 611234-31-2P	611234-32-3P	611234-33-4P
611234-34-5P	611234-35-6P	611234-36-7P
611234-37-8P	611234-38-9P	611234-40-3P
611234-84-5P	611234-85-6P	611234-86-7P
611234-87-8P	611234-88-9P	611234-89-0P
611234-90-3P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of indolylmaleimides for treating diseases or disorders
mediated by T lymphocytes and/or PKC)

RN 611234-31-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-(4,7-diazaspiro[2.5]oct-7-yl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 611234-32-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-(4,7-diazaspiro[2.5]oct-7-yl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 611234-31-2


CMF C29 H26 N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 611234-33-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-[(3R)-3-methyl-1-piperazinyl]-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611234-34-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-(4,7-diazaspiro[2.5]oct-7-yl)-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 611234-35-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[(3R)-3-methyl-1-piperazinyl]-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-36-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-[(3S)-3-methyl-1-piperazinyl]-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-37-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[(3S)-3-methyl-1-piperazinyl]-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-38-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[(3S)-3,4-dimethyl-1-piperazinyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-40-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[3-[(3S)-3,4-dimethyl-1-piperazinyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 611234-84-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[2-[(3S)-3-methyl-1-piperazinyl]-4-quinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 611234-85-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[2-[(3R)-3-methyl-1-piperazinyl]-4-quinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-86-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[2-[(3R)-3-methyl-1-piperazinyl]-4-quinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611234-87-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[2-[4-(phenylmethyl)-1-piperazinyl]-4-quinolinyl]- (CA INDEX NAME)




RN 611234-88-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[2-[4-(phenylmethyl)-1-piperazinyl]-4-quinolinyl]- (CA INDEX NAME)




RN 611234-89-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[2-(1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)



RN 611234-90-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[2-(1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:795114 CAPLUS

DOCUMENT NUMBER: 140:42054

TITLE: Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin

D1-CDK4 inhibitors

AUTHOR(S): Sanchez-Martinez, Concha; Shih, Chuan; Faul, Margaret M.; Zhu, Guoxin; Paal, Michael; Somoza, Carmen; Li, Tiechao; Kumrich, Christine A.; Winneroski, Leonard L.; Xun, Zhou; Brooks, Harold B.; Patel, Bharvin K. R.; Schultz, Richard M.; DeHahn, Tammy B.; Spencer, Charles D.; Watkins, Scott A.; Considine, Eileen; Dempsey, Jack A.; Ogg, Catherine A.; Campbell, Robert M.; Anderson, Bryan A.; Wagner, Jill

CORPORATE SOURCE: DCR&T, Lilly Spain S.A., Madrid, 28108, Spain

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(21), 3835-3839

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:42054


IT 221233-51-8P 635300-93-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of maleimides via heterocyclization of indolylglyoxylate with arylacetamides followed by elimination in the preparation of arenopyrrolocarbazoles as cyclin D1-CDK4 inhibitors)


RN 221233-51-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 635300-93-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(4-pyridinyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:743245 CAPLUS

DOCUMENT NUMBER: 139:307698
 TITLE: Synthesis of Aryl- and Heteroaryl[a]pyrrolo[3,4-c]carbazoles
 AUTHOR(S): Sanchez-Martinez, Concha; Faul, Margaret M.; Shih, Chuan; Sullivan, Kevin A.; Grutsch, John L.; Cooper, Jeremy T.; Kolis, Stanley P.
 CORPORATE SOURCE: Lilly S.A., Alcobendas, 28108, Spain
 SOURCE: Journal of Organic Chemistry (2003), 68(21), 8008-8014
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:307698
 IT 221233-51-8P 610312-82-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aryl- and hetero[a]pyrrolo[3,4-c]carbazoles by photochem. oxidation and Heck cyclization)
 RN 221233-51-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 610312-82-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(2-bromo-1-naphthalenyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
 REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:737721 CAPLUS
 DOCUMENT NUMBER: 139:276815
 TITLE: Preparation of 3-(indol-3-yl) 4-heteroaryl substituted

pyrrole-2,5-diones as GSK-3 β inhibitors

INVENTOR(S): Albaugh, Pamela Ann; Ammenn, Jochen; Burkholder, Timothy Paul; Clayton, Joshua Ryan; Conner, Scott Eugene; Cunningham, Brian Eugene; Engler, Thomas Albert; Furness, Kelly Wayne; Henry, James Robert; Li, Yihong; Malhotra, Sushant; Tebbe, Mark Joseph; Zhu, Guoxin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.

SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076398	A2	20030918	WO 2003-US5052	20030305
WO 2003076398	A3	20040226		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2477984	A1	20030918	CA 2003-2477984	20030305
AU 2003217596	A1	20030922	AU 2003-217596	20030305
EP 1487822	A2	20041222	EP 2003-713551	20030305
EP 1487822	B1	20070801		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1639152	A	20050713	CN 2003-805453	20030305
JP 2005530707	T	20051013	JP 2003-574619	20030305
AT 368657	T	20070815	AT 2003-713551	20030305
ES 2289274	T3	20080201	ES 2003-713551	20030305
IN 2004KN01260	A	20060505	IN 2004-KN1260	20040830
MX 2004008671	A	20041206	MX 2004-8671	20040907
US 20050288321	A1	20051229	US 2005-506029	20050519
US 7405305	B2	20080729		

PRIORITY APPLN. INFO.:

US 2002-363375P	P	20020308
US 2002-369433P	P	20020402
WO 2003-US5052	W	20030305

OTHER SOURCE(S): MARPAT 139:276815


IT 604008-37-9P 604010-62-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(indol-3-yl) 4-heteroaryl substituted pyrrole-2,5-diones as GSK-3 β inhibitors)


RN 604008-37-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[5-[3-(diethylamino)propoxy]-1-(1-methylethyl)-1H-indol-3-yl]-4-furo[3,2-c]pyridin-7-yl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 604010-62-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[7-[3-(diethylamino)propyl]-1-(1-methylethyl)-1H-indol-3-yl]-4-furo[3,2-c]pyridin-7-yl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2003:236058 CAPLUS
 DOCUMENT NUMBER: 139:127404
 TITLE: Synthesis of quinolinyl/isoquinolinyl[*a*]pyrrolo [3,4-*c*] carbazoles as cyclin D1/CDK4 inhibitors
 AUTHOR(S): Zhu, Guoxin; Conner, Scott; Zhou, Xun; Shih, Chuan; Brooks, Harold B.; Considine, Eileen; Dempsey, Jack A.; Ogg, Cathy; Patel, Bharvin; Schultz, Richard M.; Spencer, Charles D.; Teicher, Beverly; Watkins, Scott A.
 CORPORATE SOURCE: A Division of Eli Lilly and Company, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, 46285, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1231-1235
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.


DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:127404
 IT 569337-79-7P 569337-86-6P 569337-88-8P
 569337-90-2P 569337-93-5P 569337-99-1P
 569338-01-8P 569338-02-9P 569338-03-0P
 569338-04-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis of quinolinylisoquinolinylpyrrolocarbazoles as cyclin
 D1-CDK4 inhibitors)
 RN 569337-79-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(4-isoquinolinyl)- (CA INDEX
 NAME)




RN 569337-86-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-(4-
 isoquinolinyl)- (CA INDEX NAME)




RN 569337-88-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-(4-hydroxybutyl)-1H-indol-3-yl]-4-(4-
 isoquinolinyl)- (CA INDEX NAME)




RN 569337-90-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[7-(2-hydroxyethyl)-1H-indol-3-yl]-4-(4-isoquinolinyl)- (CA INDEX NAME)




RN 569337-93-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(4-quinolinyl)- (CA INDEX NAME)




RN 569337-99-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(3-quinolinyl)- (CA INDEX NAME)




RN 569338-01-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-(3-quinolinyl)- (CA INDEX NAME)




RN 569338-02-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(6-chloro-1H-indol-3-yl)-4-(4-quinolinyl)- (CA INDEX NAME)



RN 569338-03-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(6-methoxy-1H-indol-3-yl)-4-(4-quinolinyl)- (CA INDEX NAME)



RN 569338-04-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-(4-quinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:368469 CAPLUS
 DOCUMENT NUMBER: 136:386017
 TITLE: Preparation of indolylmaleimide derivatives as protein kinase c inhibitors
 INVENTOR(S): Albert, Rainer; Cooke, Nigel Graham; Cottens, Sylvain; Ehrhardt, Claus; Evenou, Jean-Pierre; Sedrani, Richard; Von Matt, Peter; Wagner, Juergen; Zenke, Gerhard
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038561	A1	20020516	WO 2001-EP12785	20011105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2428133	A1	20020516	CA 2001-2428133	20011105
AU 2002021810	A	20020521	AU 2002-21810	20011105
US 20030069424	A1	20030410	US 2001-7368	20011105
US 6645970	B2	20031111		
EP 1337527	A1	20030827	EP 2001-993604	20011105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015193	A	20040203	BR 2001-15193	20011105
JP 2004513168	T	20040430	JP 2002-541095	20011105
JP 4234426	B2	20090304		
NZ 525656	A	20041224	NZ 2001-525656	20011105
AU 2002221810	B2	20050623	AU 2002-221810	20011105
NZ 535616	A	20060331	NZ 2001-535616	20011105
CN 1253449	C	20060426	CN 2001-819992	20011105
IL 155618	A	20070704	IL 2001-155618	20011105

RU 2329263	C2	20080720	RU 2003-115429	20011105
HU 2003001651	A2	20081028	HU 2003-1651	20011105
EP 2070921	A1	20090617	EP 2009-151894	20011105
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, RO, SI				
TW 290553	B	20071201	TW 2001-90127656	20011107
KR 748386	B1	20070810	KR 2003-705805	20030425
ZA 2003003426	A	20040422	ZA 2003-3426	20030505
IN 2003CN00663	A	20050415	IN 2003-CN663	20030505
NO 2003002034	A	20030704	NO 2003-2034	20030506
MX 2003004037	A	20030819	MX 2003-4037	20030507
US 20040053949	A1	20040318	US 2003-660442	20030911
US 7220774	B2	20070522		
AU 2005202387	A1	20050623	AU 2005-202387	20050601
AU 2005202387	B2	20090326		
US 20070155817	A1	20070705	US 2007-708840	20070220
US 20070184061	A1	20070809	US 2007-708841	20070220
US 20070191401	A1	20070816	US 2007-708843	20070220
NO 2007001232	A	20030704	NO 2007-1232	20070306
IN 2007CN02652	A	20071012	IN 2007-CN2652	20070619
KR 2008014934	A	20080214	KR 2008-702849	20080201

PRIORITY APPLN. INFO.:

US 2000-246400P	P	20001107
US 2001-283705P	P	20010413
AU 2002-21810	A3	20011105
AU 2002-221810	A3	20011105
EP 2001-993604	A3	20011105
NZ 2001-525656	A1	20011105
US 2001-7368	A1	20011105
WO 2001-EP12785	W	20011105
IN 2003-CN663	A3	20030505
US 2003-660442	A3	20030911
KR 2006-717472	A3	20060829

OTHER SOURCE(S): MARPAT 136:386017


IT 425636-80-2P	425636-81-3P	425636-82-4P
425636-83-5P	425636-84-6P	425636-85-7P
425636-86-8P	425636-87-9P	425636-88-0P
425636-89-1P	425636-90-4P	425636-91-5P
425636-92-6P	425636-93-7P	425636-94-8P
425636-95-9P	425636-96-0P	425636-97-1P
425636-98-2P	425637-00-9P	425637-02-1P
425637-04-3P	425637-06-5P	425637-08-7P
425637-10-1P	425638-30-8P	425638-31-9P
425638-32-0P	425638-33-1P	425638-34-2P
425638-35-3P	425638-36-4P	425638-37-5P
425638-38-6P	425638-39-7P	425638-40-0P
425638-41-1P	425638-42-2P	425638-43-3P
425638-44-4P	425638-45-5P	425638-46-6P
425638-47-7P	426214-41-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; preparation of indolylmaleimide derivs. as protein kinase c inhibitors)


RN 425636-80-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(dimethylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-81-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(1-pyrrolidinyloxy)]-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-82-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-[(2-hydroxyethyl)methylamino]ethoxy]]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-83-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(3-methoxy-1-naphthalenyl)- (CA INDEX NAME)




RN 425636-84-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(3-hydroxy-1-naphthalenyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 425636-85-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-[3-(dimethylamino)propoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-86-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclopropylmethylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-87-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclopropylmethylamino)ethoxy]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-88-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclopropylamino)ethoxy]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-89-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[[1-(methylamino)cyclopropyl]methoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-90-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[[1-(methylamino)cyclopropyl]methoxy]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-91-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-(4-methyl-1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-92-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-(4-methyl-1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-93-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-(1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-94-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-(1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-95-9 CAPLUS
 CN 1-Piperazinecarboxaldehyde, 4-[4-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-naphthalenyl]- (CA INDEX NAME)




RN 425636-96-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(1-piperidinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 425636-97-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(butylmethylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-98-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclohexylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425637-00-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(4-methyl-1-piperidinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425637-02-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(2-methyl-1-pyrrolidinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425637-04-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(4-hydroxy-1-piperidinyl)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425637-06-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 425637-08-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-(2-[1,4'-bipiperidin]-1'-ylethoxy)-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 425637-10-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(3-hydroxy-1-piperidinyl)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-30-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-[2-(dimethylamino)ethoxy]-4-quinolinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-31-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[2-(4-methyl-1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)




RN 425638-32-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(2-chloro-4-quinolinyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-33-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(2-methoxy-6-methyl-4-quinolinyl)- (CA INDEX NAME)




RN 425638-34-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[2-(dimethylamino)ethoxy]-6-methyl-4-quinolinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-35-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[3-(dimethylamino)propoxy]-6-methyl-4-quinolinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-36-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(2-methoxy-4-quinolinyl)- (CA INDEX NAME)




RN 425638-37-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(2-methoxy-7-methyl-4-quinolinyl)- (CA INDEX NAME)




RN 425638-38-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[2-(dimethylamino)ethoxy]-7-methyl-4-quinolinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-39-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[7-methyl-2-(4-methyl-1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)




RN 425638-40-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[7-methyl-2-(4-methyl-1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)




RN 425638-41-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[2-(4-methyl-1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)




RN 425638-42-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[6-methyl-2-(4-methyl-1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)




RN 425638-43-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[6-methyl-2-(4-methyl-1-piperazinyl)-4-quinolinyl]- (CA INDEX NAME)




RN 425638-44-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-(4-cyclopentyl-1-piperazinyl)-4-quinolinyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-45-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-(4-cyclopentyl-1-piperazinyl)-4-quinolinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-46-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[4-(3-hydroxypropyl)-1-piperazinyl]-4-quinolinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425638-47-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-[4-[3-(dimethylamino)propyl]-1-piperazinyl]-4-quinolinyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 426214-41-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[methyl-2-[4-(2-pyrimidinyl)-1-piperazinyl]-4-quinolinyl]- (9CI) (CA INDEX NAME)




D1-Me


IT 425638-69-3P 425638-70-6P 425638-71-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of indolylmaleimide derivs. as protein kinase c
 inhibitors)
 RN 425638-69-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-
 [(methylsulfonyl)oxy]ethoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 425638-70-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-[[tris(1-
 methylethyl)silyl]oxy]ethoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425638-71-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-(2-hydroxyethoxy)-1-naphthalenyl]-4-(1H-indol-3-
 yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:292783 CAPLUS
 DOCUMENT NUMBER: 135:122654
 TITLE: Phenyliodine(III) bis(trifluoroacetate)-mediated oxidation of bisindolylmaleimides to indolo[2,3-a]carbazoles
 AUTHOR(S): Faul, M. M.; Sullivan, K. A.
 CORPORATE SOURCE: Chemical Process Research and Development Division, Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SOURCE: Tetrahedron Letters (2001), 42(19), 3271-3273
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:122654
 IT 125313-42-0
 RL: RCT (Reactant); RACT (Reactant or reagent) (failed PIFA-mediated oxidation)
 RN 125313-42-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)
 REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1999:83376 CAPLUS

DOCUMENT NUMBER: 130:237430
 TITLE: A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides
 AUTHOR(S): Faul, Margaret M.; Winneroski, Leonard L.; Krumrich, Christine A.
 CORPORATE SOURCE: Chemical Process Research and Development Division, Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285-4813, USA
 SOURCE: Tetrahedron Letters (1999), 40(6), 1109-1112
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 130:237430
 IT 125313-42-0P 221233-51-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of maleimides by condensation of glyoxylate esters with acetamides)
 RN 125313-42-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)




RN 221233-51-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1995:338467 CAPLUS
 DOCUMENT NUMBER: 122:150861
 ORIGINAL REFERENCE NO.: 122:27649a, 27652a
 TITLE: 2-Aryl-indolyl maleimides - novel and potent

inhibitors of protein kinase C
 AUTHOR(S): Hendricks, Robert T.; Sherman, D.; Strulovici, Berta; Broka, Chris A.
 CORPORATE SOURCE: Inst. Org. Chem., Syntex Discovery Res., Palo Alto, CA, 94304, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(1), 67-72
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 161404-52-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (preparation of arylindolyl maleimides as novel and potent inhibitors of protein kinase C in relation to antitumor activity)
 RN 161404-52-0 CAPLUS
 CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1-naphthalenyl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

L3 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1992:41230 CAPLUS
 DOCUMENT NUMBER: 116:41230
 ORIGINAL REFERENCE NO.: 116:7065a,7068a
 TITLE: Inhibitors of protein kinase C. 1.
 2,3-bisarylmaleimides
 AUTHOR(S): Davis, Peter D.; Hill, Christopher H.; Lawton, Geoffrey; Nixon, John S.; Wilkinson, Sandra E.; Hurst, Steven A.; Keech, Elizabeth; Turner, Susan E.
 CORPORATE SOURCE: Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
 SOURCE: Journal of Medicinal Chemistry (1992), 35(1), 177-84
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 116:41230
 IT 125313-42-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and protein kinase C inhibiting activity of)
 RN 125313-42-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA
 INDEX NAME)



OS.CITING REF COUNT: 116 THERE ARE 116 CAPLUS RECORDS THAT CITE THIS
 RECORD (116 CITINGS)

L3 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1990:98378 CAPLUS
 DOCUMENT NUMBER: 112:98378
 ORIGINAL REFERENCE NO.: 112:16731a,16734a
 TITLE: Preparation of 3-(3-indolyl)pyrrole-2,5-diones and
 analogs as protein kinase inhibitors
 INVENTOR(S): Davis, Peter David; Hill, Christopher Huw; Lawton,
 Geoffrey
 PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 328026	A1	19890816	EP 1989-102025	19890206
EP 328026	B1	19930428		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8900865	A	19891025	ZA 1989-865	19890203
CZ 280738	B6	19960417	CZ 1989-752	19890203
SK 278989	B6	19980506	SK 1989-752	19890203
AU 8929658	A	19890810	AU 1989-29658	19890206
AU 623630	B2	19920521		
HU 49348	A2	19890928	HU 1989-554	19890206
HU 201054	B	19900928		
US 5057614	A	19911015	US 1989-307104	19890206
AT 88704	T	19930515	AT 1989-102025	19890206
CA 1320194	C	19930713	CA 1989-590178	19890206
ES 2054890	T3	19940816	ES 1989-102025	19890206
DK 8900558	A	19890811	DK 1989-558	19890207
DK 171891	B1	19970804		
JP 01233281	A	19890919	JP 1989-27741	19890208
JP 07030071	B	19950405		
NO 8900568	A	19890811	NO 1989-568	19890209
NO 172540	B	19930426		
NO 172540	C	19930804		
SU 1799382	A3	19930228	SU 1989-4613492	19890209

FI 8900652	A	19890811	FI 1989-652	19890210
FI 96861	B	19960531		
FI 96861	C	19960910		
US 36736	E	20000613	US 1998-14198	19980127


PRIORITY APPLN. INFO.:

	GB 1988-3048	A	19880210
	GB 1988-27565	A	19881125
	EP 1989-102025	A	19890206
	US 1989-307104	A5	19890206


IT 125313-42-0P 125314-60-5P 125314-61-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as protein kinase inhibitor)
 RN 125313-42-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA
 INDEX NAME)



RN 125314-60-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(4-pyridinyl)- (CA
 INDEX NAME)



RN 125314-61-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(3-pyridinyl)- (CA
 INDEX NAME)



OS.CITING REF COUNT: 56 THERE ARE 56 CAPLUS RECORDS THAT CITE THIS RECORD (77 CITINGS)

=>